Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cash from Financing Activities data on record, last reported at $3.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 1403.98% year-over-year to $3.4 million; the TTM value through Dec 2025 reached -$17.4 million, changed N/A, while the annual FY2025 figure was $665.0 million, 232.01% up from the prior year.
  • Cash from Financing Activities reached $3.4 million in Q4 2025 per CAI's latest filing, up from -$21.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $3.4 million in Q4 2025 and bottomed at -$21.1 million in Q3 2025.